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ABSTRACT
Introduction The main surgical dilemma during glioma 
resections is the surgeon’s inability to accurately identify 
eloquent areas when the patient is under general 
anaesthesia without mapping techniques. Intraoperative 
stimulation mapping (ISM) techniques can be used 
to maximise extent of resection in eloquent areas yet 
simultaneously minimise the risk of postoperative 
neurological deficits. ISM has been widely implemented for 
low- grade glioma resections backed with ample scientific 
evidence, but this is not yet the case for high- grade 
glioma (HGG) resections. Therefore, ISM could thus be of 
important value in HGG surgery to improve both surgical 
and clinical outcomes.
Methods and analysis This study is an international, 
multicenter, prospective three- arm cohort study of 
observational nature. Consecutive HGG patients will be 
operated with awake mapping, asleep mapping or no 
mapping with a 1:1:1 ratio. Primary endpoints are: (1) 
proportion of patients with National Institute of Health 
Stroke Scale deterioration at 6 weeks, 3 months and 6 
months after surgery and (2) residual tumour volume 
of the contrast- enhancing and non- contrast- enhancing 
part as assessed by a neuroradiologist on postoperative 
contrast MRI scans. Secondary endpoints are: (1) overall 
survival and (2) progression- free survival at 12 months 
after surgery; (3) oncofunctional outcome and (4) 
frequency and severity of serious adverse events in each 
arm. Total duration of the study is 5 years. Patient inclusion 
is 4 years, follow- up is 1 year.
Ethics and dissemination The study has been approved 
by the Medical Ethics Committee (METC Zuid- West 
Holland/Erasmus Medical Center; MEC-2020–0812). 
The results will be published in peer- reviewed academic 
journals and disseminated to patient organisations and 
media.
Trial registration number  ClinicalTrials. gov ID number 
NCT04708171 (PROGRAM- study), NCT03861299 (SAFE- 
trial)
INTRODUCTION
Gliomas are the most common malignant 
tumours of the central nervous system and 
are classified into grades 1–4, where grades 1 
and 2 consist of low- grade gliomas (LGG) and 
grades 3 and 4 represent high- grade gliomas 
(HGG).1 2 Gliomas are relatively rare (inci-
dence of 5/100 000 persons/year in Europe 
and North America), but are associated with a 
relatively high morbidity and mortality regard-
less of years of scientific efforts to improve 
clinical outcomes in these patients.1–7
Studies show that maximising the extent of 
resection of the contrast- enhancing part—
and recently, the non- contrast- enhancing part 
as well—results in improved patient survival 
rates.8–15 Moreover, patients with gross- total 
resections derived the most benefit from the 
adjuvant chemoradiotherapy compared with 
patient with subtotal resections.16 However, 
in excess of 50% of gliomas are located in or 
near eloquent areas of the brain.2 Eloquent 
Strengths and limitations of this study
 ► First multicentre prospective study directly compar-
ing awake mapping, asleep mapping and no map-
ping for glioblastoma resections in or near eloquent 
areas.
 ► International, multicenter design on a large scale, 
which will be of substantial benefit with regard to 
subgroup analyses and external generalisability of 
the results.
 ► Observational design will not exclude all possible, 
inherent forms of bias.
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areas are important areas within the brain where speech 
and/or motor functions are located. Damaging these 
areas during surgery can lead to severe and permanent 
neurological deficits that seriously impact the quality 
of life. As a consequence of this worsened condition, 
some patients are excluded for radiotherapy and chemo-
therapy, leading to suboptimal clinical outcomes.16
Thus, the main surgical problem for the surgeon is 
the inability to accurately identify these eloquent areas 
when the patient is under general anaesthesia (GA) when 
no brain mapping techniques are being used. Surgeons 
often choose a more defensive approach for tumours 
that are located in or near these areas to prevent postop-
erative neurological deficits in patients with an already 
poor prognosis.2 10 12–15 The use of intraoperative stimu-
lation (neurophysiological) mapping techniques (ISM) 
can be necessary to enable the surgeon to resect as much 
tumour as possible while preserving quality of life and 
neurological functioning in these patients.17 Mapping 
of motor- eloquent tumours can be performed while the 
patient is awake or asleep, while speech mapping can 
only be performed when the patient is awake. The use of 
mapping techniques has tremendous potential in glioma 
resections in eloquent areas, especially for HGG patients. 
However, there is currently no international consensus 
regarding the use of these techniques. The scientific 
evidence for the use of these techniques in this patient 
group is currently both inconclusive and fragmented. We 
therefore propose an international, multicenter prospec-
tive cohort study in which the use of awake and asleep 
mapping techniques in HGG patients will be evaluated.
The described research initiative will be able to study 
these techniques in a prospective setting while covering 
a breadth of centres and countries. Hence, the data 
generated in this ENCRAM (The European and North 
American Consortium and Registry for Intraoperative 
Stimulation Mapping) research collaboration will be 
able to answer multiple research questions with excellent 
generalisability, external validity and overall quality in 
both a cost- effective and practical setting.18
METHODS AND ANALYSIS
Study design
This is a international, multicenter, prospective, three- arm 
cohort study. Eligible patients are operated using awake 
mapping, asleep mapping or no mapping with a 1:1:1 ratio 
with a sequential computer- generated random number as 
subject ID. Patients with motor- eloquent tumours will be 
treated in all study arms, while speech- eloquent tumours 
will only be treated in either the awake mapping or no 
mapping arm. The PROGRAM study (prospective cohort 
study of high- grade glioma resections using awake crani-
otomy and intraoperative stimulation mapping) is similar 
to the SAFE- trial (SAFE surgery for glioblastoma patients: 
awake craniotomy versus craniotomy under general anes-
thesia: a multicenter randomized controlled trial) and is 
initiated by the same center, however, the presented study 
will be different in various ways: the PROGRAM study (1) 
will be an observational, prospective cohort study, (2) 
will include asleep mapping as an additional treatment 
arm, (3) will evaluate the extent of resection of the non- 
contrast- enhancing part of the tumour as well, (4) will 
include both WHO grade III and grade IV gliomas, (5) will 
include an oncofunctional score as one of the outcomes 
and (6) will include neurosurgical centers in the USA and 
is part of the ENCRAM Research Consortium.18
Study objectives
The primary study objective is to evaluate the safety and 
efficacy of resections with or without mapping tech-
niques (neurological morbidity and extent of resection) 
in HGG patients as expressed by National Institute of 
Health Stroke Scale (NIHSS) scores and volumetric data. 
Secondary study objectives are to study the overall survival 
(OS), progression- free survival (PFS) and oncofunctional 
outcome after resections with or without mapping tech-
niques as expressed by survival data, progression on MRI 
scans and combining postoperative volumetric/func-
tional outcomes, respectively.
Study setting and participants
Patients will be recruited for the study from the neurosur-
gical or neurological outpatient clinic or through referral 
from general hospitals of the participating neurosurgical 
hospitals, located in Europe and the USA. The study is 
open to additional participating neurosurgical centres.
Patient and public involvement statement
Patients enrolled in the SAFE- trial (awake craniotomy vs 
craniotomy under general anesthesia for glioblastoma 
patients, NCT03861299) were consulted for this study 
to include patient experiences with resections with and 
without mapping.
Inclusion criteria
In order to be eligible to participate in this study, a subject 
must meet all of the following criteria:
1. Age ≥18 years and ≤90 years.
2. Tumour diagnosed as HGG (WHO grade III/IV) on 
MRI as assessed by the neurosurgeon.
3. Tumours situated in or near eloquent areas; motor cor-
tex, sensory cortex, subcortical pyramidal tract, speech 
areas or visual areas as indicated on MRI (Sawaya grad-
ing II and II).19
4. The tumour is suitable for resection (according to neu-
rosurgeon).
5. Written informed consent.
Exclusion criteria
A potential subject who meets any of the following criteria 
will be excluded from participation in this study:
1. Tumours of the cerebellum, brainstem or midline.
2. Multifocal contrast enhancing lesions.
3. Medical reasons precluding MRI (eg, pacemaker).
4. Inability to give written informed consent.
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5. Secondary HGG due to malignant transformation 
from LGG.
6. Second primary malignancy within the past 5 years 
with the exception of adequately treated in situ carci-
noma of any organ or basal cell carcinoma of the skin.
Interventions
(1) Awake craniotomy with local anaesthesia (arm 1: 
awake mapping).
On the evening before surgery 1.5–2.0 mg lorazepam 
is administered for anxiolysis and 2×8 mg dexamethason. 
The patient is sedated with a bolus injection of propofol 
(0.5–1 mg/kg) and kept sedated with a propofol infu-
sion pump (mean: 4 mg/kg/hour) and remifentanil 
((0.5–2 µg/kg/min). Supplemental O2 might be provided 
through a nasal cannula. Patients typically receive 1–2 g 
of cefazolin and sometimes up to 1 g/kg of mannitol (all 
verified with the surgeon). The room is kept warm and 
patient covered as the goal is to have the core tempera-
ture above 36°C during motor mapping. An arterial line 
(with standard monitoring for vital signs in addition to BP 
monitoring), central venous catheter, and urinary cath-
eter are inserted. The patient is awakened and positioned 
on the table. At this point local anaesthesia for the fixation 
of the head in the Mayfield clamp and the surgical field 
is provided with a mixture of 10 mL lidocaine 2% with 
10 mL bupivacaine 0.5% plus epinephrine 1:200 000 for 
the Mayfield clamp and up to 40 mL bupivacaine 0.375% 
with epinephrine 1:200 000 for the surgical field. After 
positioning, clamp fixation and surgical field infiltration, 
patients are sedated again for the trephination until the 
dura mater is opened, after local application of some 
drops of local anaesthetics. Propofol sedation is stopped 
after opening of the dura, with the patient awakening 
with as few external stimuli as possible. Cortical stimula-
tion is performed with a bipolar electrical stimulator. The 
distance between both poles is 5 mm, and stimulation is 
performed by placing this bipolar pincet directly on the 
cortical surface and stimulating with increasing electrical 
biphasic currents of 2–12 mA (1–2 mA increasing steps, 
pulse frequency 60 Hz, single pulse phase duration of 100 
µs) until motor or speech arrest is observed. For motor 
mapping a 2 s train and for speech mapping a 5 s train 
is used, respectively. The intraoperative neurolinguistic 
test- battery is performed by a neuropsychologist/linguist, 
who will inform the neurosurgeon of any kind of speech 
arrest or dysarthria. The difference between these is not 
always clear, but can be distinguished from involuntary 
muscle contraction affecting speech. When localising the 
motor and sensory cortex, the patient is asked to report 
any unintended movement or sensation in extremities or 
face. Confirmed functional cortical areas are marked with 
a number. After completion of cortical mapping, a resec-
tion of the tumour is performed as radical as possible 
using an ultrasonic aspirator and suction tube, while 
sparing these functional areas. When the tumour margins 
or white matter is encountered or when on regular 
neuronavigation the eloquent white matter tracts are 
thought to be in close proximity, subcortical stimulation 
(biphasic currents of 8–16 mA, 1–2 mA increasing steps, 
pulse frequency 60 Hz, single pulse phase duration of 100 
µs, 2 s train) is performed to localise functional tracts. 
If subcortical tracts are identified, resection is stopped. 
During the resection of the lesion close to an eloquent 
area, the patient is involved in a continuous dialogue 
with the neuropsychologist. That way the neurosurgeon 
has ‘online’-control of these eloquent areas. In case of 
beginning disturbances of communication or of motor or 
sensory sensations the resection is cessated immediately. 
When, due to stimulation, an epileptic seizure occurs, this 
is stopped by administering some drops of iced saline on 
the just stimulated cortical area. If a seizure continues, an 
intravenous propofol or diphantoin bolus of 0.5 mg/kg is 
administrated and repeated until the seizure stops. The 
mapping procedure is temporarily halted. If the patient 
is adequate, cooperative and able to carry out tasks after 
the seizure, the mapping procedure can continue. In the 
case of refractory seizures, the mapping procedure will 
be permanently halted and the resection will continue 
under GA. After resection of the tumour a final neuro-
logical examination is performed. During closure of the 
surgical field the patient is sedated with propofol again. 
After wound closure and dressing, sedation is stopped. 
The awake patient is transferred to the post- anaesthesia 
care unit (PACU), where the patient is haemodynamically 
and neurologically monitored for 24 hours.
(2) Asleep mapping under GA (arm 2: asleep mapping).
An intravenous is started on ipsilateral hand to the 
tumour. The patient is premedicated with up to 2 mg 
of midazolam. None if altered mental status (prevent 
further increase in ICP). Arterial (ipsilateral to tumour) 
catheter is inserted after induction of anaesthesia. Anaes-
thesia goals are to decrease ICP (if high), to maintain 
adequate CPP (at least 70 mm Hg) to prevent cerebral 
ischaemia from brain retraction, and to allow intraoper-
ative cortical motor mapping. Patients typically receive 
1–2 g of cefazolin, and 4 mg of decadron before skin inci-
sion, and sometimes up to 1 g/kg of mannitol (all verified 
with the surgeon). The room is kept warm and patient 
covered as the goal is to have the core temperature above 
36°C during motor mapping. Induction with propofol. In 
case of increased ICP, have patient hyperventilate during 
preoxygenation and continue hyperventilation with mask 
as soon as possible after induction of anaesthesia. Fentanyl 
up to 5 µg/kg in divided doses throughout induction, 
prior to intubation. Adequate neuromuscular blockade 
(rocuronium) is verified prior to intubation to avoid 
coughing/straining. Eyes are taped, and at least one addi-
tional large bore intravenous is inserted. Neuromuscular 
relaxation is let to wear off for motor mapping (do not 
reverse). The patient position will depend on location of 
tumour. Anaesthesia is mainained with 70% nitrous oxide 
in oxygen, low- dose inhalation agent (less than 0.5 MAC), 
and a remifentanil (0.2 µg/kg/min) or fentanyl infusion 
(2 µg/kg/hour). Euvolaemia is maintained (Lactated 
Ringer’s). Mild hyperventilation (PaCO2 35 mm Hg) 
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is used. Once the bone flap is removed, the surgeon 
assesses the tightness of the dura. ICP is further decreased 
if necessary (pCO2, mannitol, propofol, head up, etc). 
Once the dura is open, the goal is to avoid brain shift so 
that stereotactic navigation system can be used optimally. 
During motor mapping, the arm, leg and face are uncov-
ered to observe for movement. Stimulation is performed 
with the use of evoked potentials and continuous 
dynamic mapping/direct subcortical stimulation (CDM) 
with a monopolar stimulator (INOMED Medizintechnik, 
Germany). During stimulation, TES/MEP (transcranial 
evoked stimulation/motor evoked stimulation) regis-
tration is performed of the contralateral m. orbicularis 
oris, m. orbicularis oculi, m. biceps brachii, m. abductor 
pollicis, m. rectus femoris and m. tibialis anterior; and 
the ipsilateral m. abductor pollicis. SSEP (somatosen-
sory evoked stimulation) registration is performed of the 
contralateral n. tibialis and bilateral n. medianus. The 
pulse form is negative, with five pulses and a pulse width 
of 500 µs, ISI 4 and current between 5 and 20 mA. In 
case of poststimulation continuation of motor activity, the 
surgeon will try to stop it by applying cold saline on the 
cortex. Have propofol (10 mg/mL) in line in case of intra-
operative seizures (0.5 mg/kg for seizure suppression). 
May use neuromuscular relaxants after the last motor 
mapping. Fentanyl infusion is usually stopped at the 
beginning of closure. Remifentanil infusion is stopped 
about 10 min before end of surgery. At this point, use of 
inhalation agent may be replaced with a propofol infu-
sion (50–100 µg/kg/min). pCO2 is normalised to facili-
tate spontaneous breathing at the end of the operation. 
Use of inhalation agents (or propofol) is usually stopped 
about 10–15 min before end of surgery, and nitrous oxide 
at the end of surgery. Residual neuromuscular blockade 
is reversed once the Mayfield pins have been removed. At 
the end of the procedure all anaesthetics are stopped and 
patient is brought to the PACU (PACU/IC). Detubation 
of the patient is performed as early as possible, if patient 
fulfils the detubation criteria (>36°C body temperature, 
stable haemodynamics, sufficient spontaneous ventila-
tion, adequate response to verbal orders). Postoperative 
analgesia is provided with paracetamol intravenous or 
p.o. 1 g up to 4 dd and morphine 7.5 mg SC up to 4 dd, if 
necessary. At the PACU the patient is haemodynamically 
and neurologically monitored for 24 hours.
(3) Craniotomy under GA without mapping (arm 3: no 
mapping).
On the evening before surgery, 1.5–2.0 mg lorazepam is 
administered for anxiolysis.Sixtey min before anaesthesia 
induction, the patient receives 1 g paracetamol orally and 
7.5–15 mg midazolam orally if requested for sedation. En 
route to the operating room, 0.5–2 mg midazolam intra-
venous may be given. 1 g cefazoline is given intravenous 
for antibiotic prophylaxis before anaesthesia induction. 
GA is induced intravenously with fentanyl 0.25–0.5 mg, 
propofol 100–200 mg and cis- atracurium 10–20 mg. After 
induction of anaesthesia, the patient is orotracheally intu-
bated and mechanical ventilation is applied. Respiratory 
rate and tidal volume are adjusted to keep the patient 
normocapnic.
An arterial line (alternatively: two peripheral intrave-
nous), central venous catheter (v. basilica) and urinary 
catheter are inserted. Anaesthesia is maintained with 
propofol (up to 10 mg/kg/hour) and remifentanil 
(0.5–2 µg/kg/min). isoflurane (up to 1 MAC) and clon-
idine (1–2 µg/kg) may be added for maintenance, if 
necessary (a beta blocker or calcium channel blocker 
may be used to control BP as an alternative to clonidine). 
The fluid management is aiming for normovolaemia. 
0.9% saline solution and balanced crystalloids are used 
for maintenance, in case of blood loss >300 mL, HAES 
130/0.4 solution (hydroxyethyl starch) will be given. 
Temperature management is aiming for normothermia, 
warm- air blankets and warmed infusion lines are used. 
Arterial blood gas analysis is performed at the beginning 
of the procedure and repeated, if necessary. Electrolytes 
are controlled and substituted and hyperglycaemic will 
be treated with insulin, if necessary. The anaesthetised 
patient is positioned on the table. Local infiltration of 
the scalp is performed with 20 mL lidocaine 1% with 
epinephrine 1:200.000 to reduce bleeding. The insertion 
points of the Mayfield clamp are not infiltrated with local 
anaesthetics.
Trephination and tumour resection are performed 
without any additional neuro- psychological monitoring, 
guided by standard neuronavigation. At the end of the 
procedure, all anaesthetics are stopped and patient 
is brought to the PACU. Detubation of the patient is 
performed as early as possible, if patient fulfils the detuba-
tion criteria (>36°C body temperature, stable haemo-
dynamics, sufficient spontaneous ventilation, adequate 
response to verbal orders). Postoperative analgesia is 
provided with paracetamol intravenously or orally 1 g up 
to 4 dd and morphine 7.5 mg SC up to 4 dd, if necessary. 
At the PACU the patient is haemodynamically and neuro-
logically monitored for 24 hours.
Surgical adjuncts and additional imaging
The use of fMRI, Diffusion Tensor Imaging (DTI), ultra-
sound or 5- ALA (5- aminolevulinic acid) is allowed to be 
used in all groups on the surgeon’s indication.
Participant timeline
The flow diagram illustrates the main study procedures, 
including follow- up evaluations (figure 1). In summary, 
study patients are allocated to either the awake mapping, 
asleep mapping or no mapping group and will undergo 
evaluation at presentation (baseline) and during the 
follow- up period at 6 weeks, 3 months, 6 months and 
12 months postoperatively. Motor function will be eval-
uated using the NIHSS and Medical Research Council 
(MRC) scales. Language function will be evaluated using 
a standard neurolinguistic test- battery consisting of the 
Aphasia Bedside Check (ABC), Shortened Token Test, 
Verbal fluency, Picture description and Object naming. 
Cognitive function will be assessed using the Montreal 
 on O










pen: first published as 10.1136/bm




5Gerritsen JKW, et al. BMJ Open 2021;11:e047306. doi:10.1136/bmjopen-2020-047306
Open access
Cognitive Assessment (MoCA). Patient functioning with 
be assessed with the Karnofsky Performance Scale (KPS) 
and the ASA (American Society of Anesthesiologists) 
physical status classification system. Health- related quality 
of life (HRQoL) will be assessed with the EQ- 5D question-
naire (EuroQol Five Dimensions health questionnaire). 
OS and PFS will be assessed at 12 months postoperatively. 
We expect to complete patient inclusion in 4 years. The 
estimated duration of the study (including follow- up) will 
be 5 years.
Study procedures: clinical evaluations and follow-up
 ► Preoperative (baseline) CRF (Case Report Form).
 – Unique subject ID, demographics (centre, year, 
gender, age), tumour- specific factors (tumour vol-
ume preoperative, tumour hemisphere and lobe; 
eloquent areas), patient specific factors: preoper-
ative KPS, ASA score, neurological status (NIHSS), 
MRC grade arm/leg, neurolinguistic testing, 
MOCA, EQ- 5D.
 ► Surgery CRF
 – Type of ISM, surgeon’s rationale for modality, use 
of surgical adjuncts, use of additional imaging, ra-
diological factors: resection percentage (both the 
contrast- enhancing and non- contrast- enhancing 
part), residual volume and postoperative ischaemia.
 ► Follow- up CRFs
 – Six weeks postoperatively: histology and molecular 
markers (WHO grade, MGMT status, IDH-1 status), 
neurological status (NIHSS), MRC grade arm/leg, 
status MRC arm/MRC leg/facialis/speech/visual 
(new, worsened, improved, stable), KPS, MOCA, 
EQ- 5D.
 – Three months postoperatively: neurological status 
(NIHSS), MRC grade arm/leg, status MRC arm/
MRC leg/facialis/speech/visual (new, worsened, 
improved, stable), KPS, neurolinguistic testing, 
MOCA, EQ- 5D.
 – Six months postoperatively: neurological status 
(NIHSS), adjuvant treatment, MRC grade arm/leg, 
status MRC arm/MRC leg/facialis/speech/visual 
(new, worsened, improved, stable), KPS, MOCA, 
EQ- 5D.




The primary outcomes are (1) proportion of patients with 
NIHSS deterioration at 6 weeks, 3 months and 6 months 
postoperatively; deterioration is defined as an increase of 
at least one point on the total NIHSS score compared with 
this score at baseline and (2) residual tumour volume of 
the contrast- enhancing and non- contrast enhancing part, 
as assessed by a neuroradiologist on postoperative T1 
with contrast and T2/FLAIR MRI scan sequences using 
manual or semiautomatic volumetric analyses (Brainlab 
Elements iPlan CMF Segmentation, Brainlab AG, Munich, 
Germany or similar software).
Figure 1 Study flow diagram. DTI, diffusion tensor imaging; OS, overall survival; PFS, progression- free survival.
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Secondary outcome measures
The secondary outcomes are (1) PFS at 12 months defined 
as time from diagnosis to disease progression (occurrence 
of a new tumour lesions with a volume greater than 0.175 
cm3, or an increase in residual tumour volume of more 
than 25%) or death, whichever comes first; (2) OS at 12 
months defined as time from diagnosis to death from any 
cause; (3) oncofunctional outcome defined as the calcu-
lated coordinate of the extent of resection (or residual 
volume) on the x- axis and the postoperative NIHSS dete-
rioration (delta NIHSS) on the y- axis and (4) frequency 
and severity of serious adverse events (SAEs) in each arm.
National Institute of Health Stroke Scale
The NIHSS, or NIH Stroke Scale is a tool used by health-
care providers to objectively quantify the impairment 
caused by a stroke, but has been used extensively for 
outcome in glioma surgery because of the lack of such 
scale for neuro- oncological purposes and has been vali-
dated. The NIHSS is composed of 11 items, each of which 
scores a specific ability between a 0 and 4. For each item, 
a score of 0 typically indicates normal function in that 
specific ability, while a higher score is indicative of some 
level of impairment. The individual scores from each 
item are summed in order to calculate a patient’s total 
NIHSS score. The maximum possible score is 42 and the 
minimum score 0.
Aphasia bedside check
ABC is a short screening test to detect aphasic distur-
bances at language comprehension and language produc-
tion level at the main linguistic levels. It consists of 14 
items in total. The cut- off score for signs of aphasia is ≤12.
Shortened Token Test
The shortened Token Test is a test for language compre-
hension and for the severity of a language disorder. The 
patient is asked to point and to manipulate geometric 
forms on verbal commands. It consists of 36 items. The 
cut- off score is 29.5.
Verbal fluency (category and letter)
Category and letter fluency are tests to assess flexibility 
of verbal semantic and phonological thought processing, 
semantic memory and concept generation. The patients 
is asked to produce words of a given category (animals, 
professions) or beginning with a given letter (D, A, T) 
within a limited time span.
Picture description and object naming
The picture description test, a subtest from the CAT- NL 
(Comprehensive Aphasia Test- Netherlands), is used to 
assess semispontaneous speech in an oral and written way 
(5 min each condition). Scoring can be done according 
to the manual or more thoroughly according to the 
variables mentioned by Vandenborre et al.20 To assess 
word retrieval, various object naming tests are used: 
BNT (Boston Naming Test), DuLIP (Dutch Linguistic 
Intraoperative Protocol) and VAN- POP (Verb and Noun 
test for Perioperative Testing).
Montreal Cognitive Assessment
The MOCA is a cognitive screening test to detect mild 
impairments across several cognitive domains; attention, 
verbal memory, language, visuoconstructive skills, concep-
tual thought, calculation and orientation. The total score 
is 30, the cut- off score is ≤26.
EQ-5D
The EQ- 5D is a standardised questionnaire to assess 
the general HRQoL in five domains: mobility, self- care, 
usual activity, pain/discomfort and anxiety/depression. 
It is developed by the EuroQol Group and can also be 
used to calculate quality- adjusted life years for cost–utility 
analyses.
Sample size
This study has two primary endpoints. In order to guar-
antee that the overall type I error rate does not exceed 
5%, we apply a weighted Bonferroni correction for 
multiple testing. The sample size calculations that follow 
take that into account. For the first primary endpoint, 
proportion of patients with neurological deterioration 
at 6 weeks postsurgery, we assume a deterioration rate 
of 10% in the control group (arm 3: no mapping), and 
3% in the experimental groups (arm 1 and 2: awake and 
asleep mapping). A two- sample test for proportions with 
continuity correction requires 411 patients (137 per arm) 
in total in order to detect the above- mentioned differ-
ence of 7% with 80% power at a 4% significance level. 
For the second primary endpoint, proportion of patients 
without residual contrast- enhancing tumour on postoper-
ative MRI, we assume a success rate of 25% in the control 
group (arm 3: no mapping), and 50% in the experimental 
groups (arm 1 and 2: awake and asleep mapping). A two- 
sample test for proportions with continuity correction 
requires 188 patients (94 per arm) in total in order to 
detect the above- mentioned difference of 25% with 80% 
power at a 1% significance level. In order to power the 
study for both primary endpoints, we should include the 
larger required number of patients, that is, 411. A total 
of 411 eligible and evaluable patients in three arms allow 
the difference of 25% in proportion of patients without 
residual tumour to be detected with 88% power. Taking 
into account possible ineligibility and withdrawal of 
consent (we estimate this at 10%), a total of 453 patients 
will be included (151 patients per arm).
Data collection
All patient data are collected using the electronic data 
software Castor EDC (Electronic Data Capture). This 
software allows built- in logical checks and validations to 
promote data quality. Data entry and group allocation is 
performed by the study coordinator or locally by trained 
physicians and research nurses under supervision of the 
local investigator.
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Data analysis
All analyses will be according the intention to treat prin-
ciple, restricted to eligible patients. Patients initially regis-
tered but considered ineligible afterwards based on the 
histological analysis on tissue extracted during surgery, 
will be excluded from all analyses.
Primary study parameters
The primary endpoints will be analysed using multivar-
iate logistic regression. Subgroup analyses for tumour 
grade (WHO grade III/IV), preoperative neurological 
morbidity, preoperative tumour volume, patient’s age (in 
10- year age brackets) and tumour location/eloquence 
will be performed.
We will be including a stratification factor in the 
primary analysis model with each 10 observed events 
using the order of prognostic value as mentioned in the 
paragraph above, where the first 10 events will be used to 
estimate the effect of the arm. This rule will be applied 
in case less than 40 patients in total develop neurological 
deterioration. In the so constructed multivariate logistic 
regression model the treatment arm effect will be tested 
at 4% significance level. The primary analysis of propor-
tion of patients without residual contrast- enhancing and 
non- contrast- enhancing tumour consist of a multivariate 
logistic regression, where arm effect is corrected for all 
minimisation factors. In this model the group effect will 
be tested at 1% significance level. Manual or semiauto-
matic segmentation will be performed on axial T1 and 
T2/FLAIR MRI contrast enhanced slices to measure 
preoperative and postoperative tumour volume. A deter-
mination of volumes will be calculated blinded for the 
treatment group.
Secondary study parameters
The Kaplan- Meier method will be used to estimate PFS 
and OS proportions per treatment group at appropriate 
time points, while the Greenwood estimate of the SE (stan-
dard error) will be used to construct the corresponding 
95% CI. Multivariate cox proportional hazards models 
will be built for PFS and OS where treatment group effect 
will be corrected for minimisation factors age group (≤55 
years vs >55 years), KPS (80–90 vs >90) and left or right 
hemisphere. Additionally, competing risk analysis will 
be used to calculate cumulative incidence of PFS (with 
competing risks progression/relapse and death without 
progression/relapse which add up to 100% at every time 
point). Oncofunctional outcome will be evaluated using 
a scatter or bubble plot with volumetric data on the x- axis 
and neurological status (NIHSS) or patient performance 
(KPS) on the y- axis. SAEs in both groups will be described.
Study monitoring
No scheduled on- site monitoring visits will be performed. 
Local investigators will remain responsible for the fact 
that the rights and well- being of patients are protected, 
the reported trial data are accurate, complete and verifi-
able from source documents and the conduct of the trial 
is in compliance with the currently approved protocol/
amendment(s), with GCP (Good Clinical Practice) and 
with the applicable regulatory requirement(s). Direct 
access to source documentation (medical records) must 
be allowed for the purpose of verifying that the data 
recorded in the CRF are consistent with the original 
source data. No data safety monitoring board will be 
installed: all interventions are care- as- usual and patients 
are allocated without randomisation.
Adverse events and SAEs
AEs (adverse events) are defined as any undesirable expe-
rience occurring to a subject during the study, whether or 
not considered related to neurosurgery. All AEs reported 
spontaneously by the subject or observed by the investi-
gator or his staff will be recorded from start of surgery 
until 6 weeks after surgery. SAEs (serious adverse events) 
are any untoward medical occurrence or effect that results 
in death; is life- threatening (at the time of the event); 
requires hospitalisation or prolongation of existing inpa-
tients’ hospitalisation; results in persistent or significant 
disability or incapacity or any other important medical 
event that did not result in any of the outcomes listed 
above due to medical or surgical intervention, but could 
have been based on appropriate judgement by the inves-
tigator. An elective hospital admission will not be consid-
ered as an SAE. Most of the (serious) adverse effects of 
treatments be mainly related to the surgery: post opera-
tive pain, nausea and anaemia (in case of massive blood 
loss), Infections, intracranial haemorrhage, epilepsy, 
aphasia, paresis/paralysis in arms or/and legs.
Most of the (serious) adverse effects of treatments 
(awake surgery or surgery under generalised anaesthesia) 
will be mainly related to the surgery: postoperative pain, 
nausea and anaemia (in case of massive blood loss), 
infections, intracranial haemorrhage, epilepsy, aphasia, 
paresis/paralysis in arms or/and legs. The neurological 
morbidity is under investigation in this trial and well- 
known risk/complications of the craniotomy and can be 
attributed to the nature of the operation. Neurosurgical 
clinics are well adapted to prevent and treat such events. 
SAEs will be collected through routine data management.
Publication of results
Trial results will be published in an international journal, 
communicated to neurological and neurosurgical associ-
ations and presented at (inter)national congresses.
ETHICS AND DISSEMINATION
The study has been approved by the Medical Ethics 
Committee (METC Zuid- West Holland/Erasmus Medical 
Center; MEC-2020–0812) and is conducted in compli-
cance with the European Union Clinical Trials Directive 
(2001/20/EC) and the principles of the Declaration of 
Helsinki (2013). The results of the study will be published 
in peer- reviewed academic journals and disseminated to 
patient organisations and media.
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DISCUSSION
Neurosurgeons face a major dilemma during glioma 
surgery: maximising extent of resection while minimising 
risk of postoperative neurological deficits. The use of 
awake or asleep mapping techniques has the potential to 
equip the surgeon intraoperatively with the needed infor-
mation to balance these two surgical goals.
A substantial amount of evidence is available on 
the usefulness of awake mapping to increase resec-
tion percentage while preserving quality of life in LGG 
patients.21–32 In contrast, only very few studies have 
reported the use of awake mapping in HGG patients, 
although this technique could be of important value 
in these patients as well.17 21 23–25 32 Recent retrospective 
evidence showed that glioblastoma patients operated with 
awake mapping had significant less postoperative neuro-
logical morbidity and significantly higher percentage 
of total resections.33 34 In patients with motor- eloquent 
tumours, the use of asleep mapping techniques with 
evoked potentials or CDM can be a viable alternative to 
preserve these functional tracts.35–37
There is a clear need for solid prospective evidence 
of the use of these techniques in HGG patients. The 
presented international neurosurgical research consor-
tium will provide the needed infrastructure to perform 
ongoing large- scale data collection.18 This study aims to 
evaluate whether the use of awake or asleep mapping is 
the appropriate answer to the surgeon’s surgical dilemma 
during HGG resections. Furthermore, it will be the first to 
directly compare awake and asleep mapping techniques 
in their ability to improve patient outcomes for neuro-
logical morbidity, quality of life and survival. Last, using 
various multivariate analyses, there will be an additional 
focus on identifying the best surgical choice in subgroups 
of HGG patients.
Trial status
The study will start at 1 April 2021 and is open to addi-
tional participating neurosurgical centers.
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